An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
Recruiting · NCT05106387
Conditions: Chronic Kidney Disease (CKD)
At a glance
- Research payments reported, 2025
- $165,178
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 20
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- Noninterventional (drug)
- Dates
- Started 2023-10-19; completion 2028-02-23
- Results posted
- Not yet
The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347). No study drug will be given during this study.
From ClinicalTrials.gov, last updated 2026-09-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $165,178 in research payments for this study in 2025 (84 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Stanley Jordan, MD Nephrology (Kidney) · West Hollywood, CA
- Robert R. Redfield, MD Transplant Surgery · Orange, CA
- Flavio G. Vincenti, M.D. Internal Medicine · San Francisco, CA
- Abhishek Kumar, M.D. Nephrology (Kidney) · New Haven, CT
- John Friedewald, MD Nephrology (Kidney) · Chicago, IL
- Raja Kandaswamy, MD General Surgery · Minneapolis, MN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $38,119
- Hospital of Univ of Pennsylvania, PA $38,038
- Regents of the University of Minnesota $36,091
- Northwestern University $32,190
- Cedars-Sinai Medical Center, CA $18,400
- Yale University $2,340
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.